<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">problendo</journal-id><journal-title-group><journal-title xml:lang="ru">Проблемы Эндокринологии</journal-title><trans-title-group xml:lang="en"><trans-title>Problems of Endocrinology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0375-9660</issn><issn pub-type="epub">2308-1430</issn><publisher><publisher-name>Endocrinology Research Centre</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/probl2017636385-391</article-id><article-id custom-type="elpub" pub-id-type="custom">problendo-8699</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Обзоры</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Reviews</subject></subj-group></article-categories><title-group><article-title>Роль почек в гомеостазе глюкозы</article-title><trans-title-group xml:lang="en"><trans-title>The role of the kidneys in glucose homeostasis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1316-5245</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мкртумян</surname><given-names>Ашот Мусаелович</given-names></name><name name-style="western" xml:lang="en"><surname>Mkrtumyan</surname><given-names>Ashot M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., проф.</p></bio><bio xml:lang="en"><p>MD, Professor</p></bio><email xlink:type="simple">vagrashot@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Маркова</surname><given-names>Татьяна Николаевна</given-names></name><name name-style="western" xml:lang="en"><surname>Markova</surname><given-names>Tatyana N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н.</p></bio><bio xml:lang="en"><p>MD</p></bio><email xlink:type="simple">markovatn18@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8270-5626</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мищенко</surname><given-names>Надежда Константиновна</given-names></name><name name-style="western" xml:lang="en"><surname>Mishchenko</surname><given-names>Nadezhda K.</given-names></name></name-alternatives><email xlink:type="simple">mischencko.nadejda2015@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>&lt;p&gt;ГОУ ВПО &amp;laquo;Московский государственный медико-стоматологический университет им. А.И. Евдокимова&amp;raquo;&lt;/p&gt;</institution><country>Россия</country></aff><aff xml:lang="en"><institution>&lt;p&gt;A.I. Evdokimov Moscow State University of Medicine and Dentistry&lt;/p&gt;</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>&lt;p&gt;ГОУ ВПО &amp;laquo;Московский государственный медико-стоматологический университет им. А.И. Евдокимова&amp;raquo;;&amp;nbsp;&amp;laquo;Городская клиническая больница №52&amp;raquo; Департамента здравоохранения Москвы&lt;/p&gt;</institution><country>Россия</country></aff><aff xml:lang="en"><institution>&lt;p&gt;A.I. Evdokimov Moscow State University of Medicine and Dentistry;&amp;nbsp;City Clinical Hospital №52&lt;/p&gt;</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>11</day><month>02</month><year>2018</year></pub-date><volume>63</volume><issue>6</issue><fpage>385</fpage><lpage>391</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Мкртумян А.М., Маркова Т.Н., Мищенко Н.К., 2017</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="ru">Мкртумян А.М., Маркова Т.Н., Мищенко Н.К.</copyright-holder><copyright-holder xml:lang="en">Mkrtumyan A.M., Markova T.N., Mishchenko N.K.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.probl-endojournals.ru/jour/article/view/8699">https://www.probl-endojournals.ru/jour/article/view/8699</self-uri><abstract><p>До недавнего времени основная функция почек в обеспечении гомеостаза глюкозы отводилась процессу деградации молекул инсулина. Однако результаты многочисленных исследований показали, что почки участвуют в обеспечении энергетических потребностей организма благодаря трем ключевым процессам: глюконеогенезу, утилизации молекул глюкозы и их реабсорбции. Особенностью глюконеогенеза, протекающего в почках, является его зависимость от времени, прошедшего после последнего приема пищи. Так, в постабсорбтивный период глюконеогенез, протекающий в корковом веществе почек, обеспечивает до 90% глюкозы, поступающей в кровеносное русло, а в постпрандиальный период — до 60%. Реабсорбция глюкозы из клубочкового фильтрата происходит в проксимальных извитых канальцах с помощью натрий-глюкозных котранспортеров, среди которых наибольшее значение имеют натрий-глюкозные ко-транспортеры 2-го типа (SGLT2). Известно, что клетки проксимальных извитых канальцев почек больных сахарным диабетом 2-го типа (CД2) содержат значительно большее количество SGLT2 белков, чем те же клетки здоровых лиц. Выяснение важной роли почек в гомеостазе глюкозы привело к изучению новых звеньев патогенеза СД2 и созданию перспективного подхода в его лечении — применению ингибиторов SGLT2.</p></abstract><trans-abstract xml:lang="en"><p>Until recently, in was believed that degradation of insulin is the main function of the kidneys in maintaining glucose homeostasis. The results of numerous studies showed that the kidneys are involved in filling the energy needs of the body due to the following three key processes: gluconeogenesis, uptake and reabsorption of glucose molecules. The characteristic feature of gluconeogenesis that occurs in the kidneys lies in the fact that it depends on the time elapsed since the last meal. Thus, gluconeogenesis that occurs in the cortical substance of the kidneys provides up to 90% of the glucose entering the blood in the post-absorptive period and up to 60% in the postprandial period. Glucose reabsorption from the glomerular filtrate occurs in the proximal convoluted tubules assisted by sodium-glucose cotransporters, sodium-glucose cotransporters 2 (SGLT2) being the most important of them. It is known that the cells of the proximal convoluted tubules of the kidneys in patients with type 2 diabetes mellitus (DM2) contain significantly more SGLT2 proteins compared to those of healthy individuals. The discovery of the important role of the kidneys in glucose homeostasis led to investigation of the new links in DM2 pathogenesis and the development of a promising approach to its treatment using SGLT2 inhibitors.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>почки</kwd><kwd>глюкоза</kwd><kwd>сахарный диабет 2-го типа</kwd><kwd>ингибитор натрий-глюкозного котранспортера 2-го типа</kwd></kwd-group><kwd-group xml:lang="en"><kwd>kidneys</kwd><kwd>glucose</kwd><kwd>type 2 diabetes mellitus</kwd><kwd>sodium-glucose cotransporter 2 inhibitor</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab. 2012;14(1):5-14. doi: 10.1111/j.1463-1326.2011.01511.x</mixed-citation><mixed-citation xml:lang="en">DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab. 2012;14(1):5-14. doi: 10.1111/j.1463-1326.2011.01511.x</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Аметов А.С. Сахарный диабет 2-го типа. Проблемы и решения. — М.: ГЭОТАР-Медиа; 2011. [Ametov AS. Saharnyj diabet 2 tipa. Problemy i reshenija. M: GEOTAR-Media; 2011. (In Russ.)].</mixed-citation><mixed-citation xml:lang="en">Аметов А.С. Сахарный диабет 2-го типа. Проблемы и решения. — М.: ГЭОТАР-Медиа; 2011. [Ametov AS. Saharnyj diabet 2 tipa. Problemy i reshenija. M: GEOTAR-Media; 2011. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Consoli A, Kennedy F, Miles J, Gerich J. Determination of Krebs cycle metabolic carbon exchange in vivo and its use to estimate the individual contributions of gluconeogenesis and glycogenolysis to overall glucose output in man. J Clin Invest. 1987;80(5):1303-1310. doi: 10.1172/JCI113206</mixed-citation><mixed-citation xml:lang="en">Consoli A, Kennedy F, Miles J, Gerich J. Determination of Krebs cycle metabolic carbon exchange in vivo and its use to estimate the individual contributions of gluconeogenesis and glycogenolysis to overall glucose output in man. J Clin Invest. 1987;80(5):1303-1310. doi: 10.1172/JCI113206</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Bock G, Dalla Man C, Campioni M, et al. Pathogenesis of pre-diabetes: mechanisms of fasting and postprandial hyperglycemia in people with impaired fasting glucose and/or impaired glucose tolerance. Diabetes. 2006;55(12):3536-3549. doi: 10.2337/db06-0319</mixed-citation><mixed-citation xml:lang="en">Bock G, Dalla Man C, Campioni M, et al. Pathogenesis of pre-diabetes: mechanisms of fasting and postprandial hyperglycemia in people with impaired fasting glucose and/or impaired glucose tolerance. Diabetes. 2006;55(12):3536-3549. doi: 10.2337/db06-0319</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Meyer C, Dostou J, Nadkarni V, Gerich J. Effects of physiological hyperinsulinemia on systemic, renal, and hepatic substrate metabolism. Am J Physiol. 1998;275(6 Pt 2):F915-F921.</mixed-citation><mixed-citation xml:lang="en">Meyer C, Dostou J, Nadkarni V, Gerich J. Effects of physiological hyperinsulinemia on systemic, renal, and hepatic substrate metabolism. Am J Physiol. 1998;275(6 Pt 2):F915-F921.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Berg JM, Tymoczko JL, Stryer L. Biochemistry. 5th edition [Internet]. New York: W.H. Freeman; 2002 [cited 2017 Feb 18]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK21154/?term=Biochemistry%20AND%20stryer%5Bbook %5D</mixed-citation><mixed-citation xml:lang="en">Berg JM, Tymoczko JL, Stryer L. Biochemistry. 5th edition [Internet]. New York: W.H. Freeman; 2002 [cited 2017 Feb 18]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK21154/?term=Biochemistry%20AND%20stryer%5Bbook %5D</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Stumvoll M, Meyer C, Kreider M, et al. Effects of glucagon on renal and hepatic glutamine gluconeogenesis in normal postabsorptive humans. Metabolism. 1998;47(10):1227-1232. doi: 10.1016/S0026-0495(98)90328-6</mixed-citation><mixed-citation xml:lang="en">Stumvoll M, Meyer C, Kreider M, et al. Effects of glucagon on renal and hepatic glutamine gluconeogenesis in normal postabsorptive humans. Metabolism. 1998;47(10):1227-1232. doi: 10.1016/S0026-0495(98)90328-6</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med. 2010;27(2):136-142. doi: 10.1111/j.1464-5491.2009.02894.x</mixed-citation><mixed-citation xml:lang="en">Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med. 2010;27(2):136-142. doi: 10.1111/j.1464-5491.2009.02894.x</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Nussey S, Whitehead S. Endocrinology: an integrated approach [Internet]. Oxford: BIOS Scientific Publishers; 2001 [cited 2017 Feb 21]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20821847</mixed-citation><mixed-citation xml:lang="en">Nussey S, Whitehead S. Endocrinology: an integrated approach [Internet]. Oxford: BIOS Scientific Publishers; 2001 [cited 2017 Feb 21]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20821847</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">McKay LI, Cidlowski JA. Physiologic and pharmacologic effects of corticosteroids. In: Kufe DW, Pollock RE, Weichselbaum RR, et al. (eds.). Holland-Frei Cancer Medicine. 6th edition [Internet]. Hamilton (ON): BC Decker; 2003 [cited 2017 Feb 26]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK13780/</mixed-citation><mixed-citation xml:lang="en">McKay LI, Cidlowski JA. Physiologic and pharmacologic effects of corticosteroids. In: Kufe DW, Pollock RE, Weichselbaum RR, et al. (eds.). Holland-Frei Cancer Medicine. 6th edition [Internet]. Hamilton (ON): BC Decker; 2003 [cited 2017 Feb 26]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK13780/</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Кулебякин К.Ю., Акопян Ж.А., Кочегура Т.Н. и др. Механизмы транскрипционного контроля обмена глюкозы в печени // Сахарный диабет. — 2016. — Т. 19. — №3. — C. 190—198. [Kulebyakin KY, Akopyan JA, Kochegura TN, et al. Mechanisms of transcriptional control of glucose metabolism in hepatocytes. Diabetes Mellitus. 2016;19(3):190-198. (In Russ.)]. doi: 10.14341/DM2003436-40</mixed-citation><mixed-citation xml:lang="en">Кулебякин К.Ю., Акопян Ж.А., Кочегура Т.Н. и др. Механизмы транскрипционного контроля обмена глюкозы в печени // Сахарный диабет. — 2016. — Т. 19. — №3. — C. 190—198. [Kulebyakin KY, Akopyan JA, Kochegura TN, et al. Mechanisms of transcriptional control of glucose metabolism in hepatocytes. Diabetes Mellitus. 2016;19(3):190-198. (In Russ.)]. doi: 10.14341/DM2003436-40</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Rubenstein AH, Mako ME, Horwitz DL. Insulin and the kidney. Nephron. 1975;15(3-5):306-326. doi: 10.1159/000180518</mixed-citation><mixed-citation xml:lang="en">Rubenstein AH, Mako ME, Horwitz DL. Insulin and the kidney. Nephron. 1975;15(3-5):306-326. doi: 10.1159/000180518</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Rabkin R, Ryan MP, Duckworth WC. The renal metabolism of insulin. Diabetologia. 1984;27(3):351-357. doi: 10.1007/bf00304849</mixed-citation><mixed-citation xml:lang="en">Rabkin R, Ryan MP, Duckworth WC. The renal metabolism of insulin. Diabetologia. 1984;27(3):351-357. doi: 10.1007/bf00304849</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Landau BR, Wahren J, Chandramouli V, et al. Contributions of gluconeogenesis to glucose production in the fasted state. J Clin Invest. 1996;98(2):378-385. doi: 10.1172/jci118803</mixed-citation><mixed-citation xml:lang="en">Landau BR, Wahren J, Chandramouli V, et al. Contributions of gluconeogenesis to glucose production in the fasted state. J Clin Invest. 1996;98(2):378-385. doi: 10.1172/jci118803</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Stumvoll M, Meyer C, Mitrakou A, et al. Renal glucose production and utilization: new aspects in humans. Diabetologia. 1997;40(7):749-757. doi: 10.1007/s001250050745</mixed-citation><mixed-citation xml:lang="en">Stumvoll M, Meyer C, Mitrakou A, et al. Renal glucose production and utilization: new aspects in humans. Diabetologia. 1997;40(7):749-757. doi: 10.1007/s001250050745</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Gerich JE, Meyer C, Woerle HJ, Stumvoll M. Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care. 2001;24(2):382-391. doi: 10.2337/diacare.24.2.382</mixed-citation><mixed-citation xml:lang="en">Gerich JE, Meyer C, Woerle HJ, Stumvoll M. Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care. 2001;24(2):382-391. doi: 10.2337/diacare.24.2.382</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Meyer C, Stumvoll M, Dostou J, et al. Renal substrate exchange and gluconeogenesis in normal postabsorptive humans. Am J Physiol Endocrinol Metab. 2002;282(2):E428-E434. doi: 10.1152/ajpendo.00116.2001</mixed-citation><mixed-citation xml:lang="en">Meyer C, Stumvoll M, Dostou J, et al. Renal substrate exchange and gluconeogenesis in normal postabsorptive humans. Am J Physiol Endocrinol Metab. 2002;282(2):E428-E434. doi: 10.1152/ajpendo.00116.2001</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Stumvoll M, Meyer C, Perriello G, et al. Human kidney and liver gluconeogenesis: evidence for organ substrate selectivity. Am J Physiol. 1998;274(5 Pt 1):E817-E826.</mixed-citation><mixed-citation xml:lang="en">Stumvoll M, Meyer C, Perriello G, et al. Human kidney and liver gluconeogenesis: evidence for organ substrate selectivity. Am J Physiol. 1998;274(5 Pt 1):E817-E826.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Shrayyef MZ, Gerich JE. Normal glucose homeostasis. 2010;19-35. doi: 10.1007/978-0-387-09841-8_2</mixed-citation><mixed-citation xml:lang="en">Shrayyef MZ, Gerich JE. Normal glucose homeostasis. 2010;19-35. doi: 10.1007/978-0-387-09841-8_2</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Meyer C, Dostou JM, Welle SL, Gerich JE. Role of human liver, kidney, and skeletal muscle in postprandial glucose homeostasis. Am J Physiol Endocrinol Metab. 2002;282(2):E419-E427. doi: 10.1152/ajpendo.00032.2001</mixed-citation><mixed-citation xml:lang="en">Meyer C, Dostou JM, Welle SL, Gerich JE. Role of human liver, kidney, and skeletal muscle in postprandial glucose homeostasis. Am J Physiol Endocrinol Metab. 2002;282(2):E419-E427. doi: 10.1152/ajpendo.00032.2001</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Joseph SE, Heaton N, Potter D, et al. Renal glucose production compensates for the liver during the anhepatic phase of liver transplantation. Diabetes. 2000;49(3):450-456. doi: 10.2337/diabetes.49.3.450</mixed-citation><mixed-citation xml:lang="en">Joseph SE, Heaton N, Potter D, et al. Renal glucose production compensates for the liver during the anhepatic phase of liver transplantation. Diabetes. 2000;49(3):450-456. doi: 10.2337/diabetes.49.3.450</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Stumvoll M, Chintalapudi U, Perriello G, et al. Uptake and release of glucose by the human kidney. Postabsorptive rates and responses to epinephrine. J Clin Invest. 1995;96(5):2528-2533. doi: 10.1172/jci118314</mixed-citation><mixed-citation xml:lang="en">Stumvoll M, Chintalapudi U, Perriello G, et al. Uptake and release of glucose by the human kidney. Postabsorptive rates and responses to epinephrine. J Clin Invest. 1995;96(5):2528-2533. doi: 10.1172/jci118314</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Mather A, Pollock C. Glucose handling by the kidney. Kidney Int. 2011;79:S1-S6. doi: 10.1038/ki.2010.509</mixed-citation><mixed-citation xml:lang="en">Mather A, Pollock C. Glucose handling by the kidney. Kidney Int. 2011;79:S1-S6. doi: 10.1038/ki.2010.509</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med. 2007;261(1):32-43. doi: 10.1111/j.1365-2796.2006.01746.x</mixed-citation><mixed-citation xml:lang="en">Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med. 2007;261(1):32-43. doi: 10.1111/j.1365-2796.2006.01746.x</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Wright EM, Loo DDF, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011;91(2):733-794. doi: 10.1152/physrev.00055.2009</mixed-citation><mixed-citation xml:lang="en">Wright EM, Loo DDF, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011;91(2):733-794. doi: 10.1152/physrev.00055.2009</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Dominguez JH, Song B, Maianu L, et al. Gene expression of epithelial glucose transporters: the role of diabetes mellitus. J Am Soc Nephrol. 1994;5:S29-S36.</mixed-citation><mixed-citation xml:lang="en">Dominguez JH, Song B, Maianu L, et al. Gene expression of epithelial glucose transporters: the role of diabetes mellitus. J Am Soc Nephrol. 1994;5:S29-S36.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Мкртумян А.М., Егшатян Л.В. Новый неинсулинзависимый подход к терапии сахарного диабета 2-го типа. Дапаглифлозин: результаты клинических исследований. // Эффективная фармакотерапия. Эндокринология. — 2015. — №11. — С. 17—24. [Mkrtumyan AM, Yegshatyan LV. A novel non-insulin dependent approach to therapy of type 2 diabetes mellitus. Dapagliflozin: results of clinical trials. Effective Pharmacotherapy. Endocrinology. 2015;(11):17-24. (In Russ.)].</mixed-citation><mixed-citation xml:lang="en">Мкртумян А.М., Егшатян Л.В. Новый неинсулинзависимый подход к терапии сахарного диабета 2-го типа. Дапаглифлозин: результаты клинических исследований. // Эффективная фармакотерапия. Эндокринология. — 2015. — №11. — С. 17—24. [Mkrtumyan AM, Yegshatyan LV. A novel non-insulin dependent approach to therapy of type 2 diabetes mellitus. Dapagliflozin: results of clinical trials. Effective Pharmacotherapy. Endocrinology. 2015;(11):17-24. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Bakris GL, Fonseca VA, Sharma K, Wright EM. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int. 2009;75(12):1272-1277. doi: 10.1038/ki.2009.87</mixed-citation><mixed-citation xml:lang="en">Bakris GL, Fonseca VA, Sharma K, Wright EM. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int. 2009;75(12):1272-1277. doi: 10.1038/ki.2009.87</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Wright EM. Surprising мersatility of Na+glucose cotransporters: SLC5. Physiology. 2004;19(6):370-376. doi: 10.1152/physiol.00026.2004</mixed-citation><mixed-citation xml:lang="en">Wright EM. Surprising мersatility of Na+glucose cotransporters: SLC5. Physiology. 2004;19(6):370-376. doi: 10.1152/physiol.00026.2004</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Wright EM. Renal Na(+)-glucose cotransporters. Am J Physiol Renal Physiol. 2001;280(1): F10-F18.</mixed-citation><mixed-citation xml:lang="en">Wright EM. Renal Na(+)-glucose cotransporters. Am J Physiol Renal Physiol. 2001;280(1): F10-F18.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Santer R, Calado J. Familial renal glucosuria and SGLT2: from a mendelian triat to a therapeutic target. Clin J Am Soc Nephrol. 2009;5(1):133-141. doi: 10.2215/cjn.04010609</mixed-citation><mixed-citation xml:lang="en">Santer R, Calado J. Familial renal glucosuria and SGLT2: from a mendelian triat to a therapeutic target. Clin J Am Soc Nephrol. 2009;5(1):133-141. doi: 10.2215/cjn.04010609</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Santer R. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol. 2003;14(11):2873-2882. doi: 10.1097/01.asn.0000092790.89332.d2</mixed-citation><mixed-citation xml:lang="en">Santer R. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol. 2003;14(11):2873-2882. doi: 10.1097/01.asn.0000092790.89332.d2</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Scholl-Burgi S, Santer R, Ehrich JHH. Long-term outcome of renal glucosuria type 0: the original patient and his natural history. Nephrology Dialysis Transplantation. 2004;19(9):2394-2396. doi: 10.1093/ndt/gfh366</mixed-citation><mixed-citation xml:lang="en">Scholl-Burgi S, Santer R, Ehrich JHH. Long-term outcome of renal glucosuria type 0: the original patient and his natural history. Nephrology Dialysis Transplantation. 2004;19(9):2394-2396. doi: 10.1093/ndt/gfh366</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Wright EM, Turk E, Zabel B, et al. Molecular genetics of intestinal glucose transport. J Clin Invest. 1991;88(5):1435-1440. doi: 10.1172/jci115451</mixed-citation><mixed-citation xml:lang="en">Wright EM, Turk E, Zabel B, et al. Molecular genetics of intestinal glucose transport. J Clin Invest. 1991;88(5):1435-1440. doi: 10.1172/jci115451</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Rahmoune H, Thompson PW, Ward JM, et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes. 2005;54(12):3427-3434. doi: 10.2337/diabetes.54.12.3427</mixed-citation><mixed-citation xml:lang="en">Rahmoune H, Thompson PW, Ward JM, et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes. 2005;54(12):3427-3434. doi: 10.2337/diabetes.54.12.3427</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Najafian M, Jahromi MZ, Nowroznejhad MJ, et al. Phloridzin reduces blood glucose levels and improves lipids metabolism in streptozotocin-induced diabetic rats. Mol Biol Rep. 2011;39(5):5299-5306. doi: 10.1007/s11033-011-1328-7</mixed-citation><mixed-citation xml:lang="en">Najafian M, Jahromi MZ, Nowroznejhad MJ, et al. Phloridzin reduces blood glucose levels and improves lipids metabolism in streptozotocin-induced diabetic rats. Mol Biol Rep. 2011;39(5):5299-5306. doi: 10.1007/s11033-011-1328-7</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Rossetti L, Smith D, Shulman GI, et al. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest. 1987;79(5):1510-1515. doi: 10.1172/jci112981</mixed-citation><mixed-citation xml:lang="en">Rossetti L, Smith D, Shulman GI, et al. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest. 1987;79(5):1510-1515. doi: 10.1172/jci112981</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Wright EM. Glucose galactose malabsorption. Am J Physiol. 1998;275(5 Pt 1):G879-G882.</mixed-citation><mixed-citation xml:lang="en">Wright EM. Glucose galactose malabsorption. Am J Physiol. 1998;275(5 Pt 1):G879-G882.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Babu A, Kim, Babu A. Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2012;313. doi: 10.2147/dmso.s22545</mixed-citation><mixed-citation xml:lang="en">Babu A, Kim, Babu A. Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2012;313. doi: 10.2147/dmso.s22545</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Sonesson C, Johansson PA, Johnsson E, Gause-Nilsson I. Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a metaanalysis. Cardiovasc Diabetol. 2016;15(1). doi: 10.1186/s12933-016-0356-y</mixed-citation><mixed-citation xml:lang="en">Sonesson C, Johansson PA, Johnsson E, Gause-Nilsson I. Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a metaanalysis. Cardiovasc Diabetol. 2016;15(1). doi: 10.1186/s12933-016-0356-y</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128. doi: 10.1056/NEJMoa1504720</mixed-citation><mixed-citation xml:lang="en">Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128. doi: 10.1056/NEJMoa1504720</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
